Australia Infant Phototherapy Device Market Size and Forecast 2025–2033

Australia Infant Phototherapy Device Market Poised to Reach US$ 2.47 Billion by 2033

Australia’s infant phototherapy device market is entering a phase of consistent and sustainable expansion, driven by rising awareness of neonatal health, increased screening for infant jaundice, and rapid advancements in non-invasive phototherapy technologies. According to Renub Research, the Australia Infant Phototherapy Device Market is projected to reach US$ 2.47 billion by 2033, up from US$ 1.88 billion in 2024, reflecting a CAGR of 3.1% during 2025–2033.

The growing recognition of neonatal jaundice as a widespread and treatable condition—paired with Australia’s strong healthcare infrastructure—continues to boost demand for safe, energy-efficient, and technologically advanced phototherapy devices. As maternity wards and NICUs (Neonatal Intensive Care Units) strive for elevated care standards, modern phototherapy systems such as LED-based and mobile units are gaining wide acceptance across the country.

Download Free Sample Report

Australia Infant Phototherapy Device Market Outlook

Infant phototherapy devices play a crucial role in treating neonatal jaundice, a highly prevalent condition in newborns caused by elevated bilirubin levels. Through exposure to blue light (typically within 460–490 nm wavelength), bilirubin breaks down into excretable forms, making phototherapy one of the safest and most effective interventions available.

In Australia, phototherapy treatment is deeply integrated into perinatal and neonatal care. With high awareness among parents, robust hospital infrastructure, and mandatory newborn screening programs in place, the adoption of phototherapy devices remains high. LED-based phototherapy modules are particularly preferred due to:

Low heat emission

High energy efficiency

Reduced maintenance and operating costs

Enhanced comfort and safety for infants

The nation’s focus on reducing infant morbidity rates—especially in preterm and low-birthweight babies—supports greater use of modern phototherapy devices. Additionally, government-led maternal and infant health improvement strategies continue to accelerate market expansion.

Key Growth Drivers in the Australia Infant Phototherapy Device Market

1. Rising Prevalence of Neonatal Jaundice

Neonatal jaundice remains one of the most common conditions among newborns in Australia, particularly affecting premature infants or those with immature liver function. Early detection and proactive treatment have become routine across hospitals, driving steady demand for phototherapy devices.

According to Australian Bureau of Statistics estimates reviewed by KPMG, Australia recorded 289,100 births in 2023, highlighting consistent demand for high-quality neonatal treatment equipment. Increased parental education and awareness of complications like kernicterus have further reinforced uptake of non-invasive phototherapy.

As diagnostic rates increase due to widespread screening and enhanced community healthcare coverage, hospitals and midwifery centers are expanding their phototherapy equipment capacity.

2. Technological Advancements in Phototherapy Equipment

Modern innovations are reshaping how neonatal jaundice is treated across Australia. The industry is shifting steadily from fluorescent lamp-based systems to advanced LED and fiber-optic phototherapy modules.

Key advancements include:

LED phototherapy systems: Lower energy consumption, longer lifespan, uniform light emission

Fiber-optic phototherapy blankets: Safe, portable, ideal for premature infants

Improved intensity controls: Deliver precise light dosages for individualized care

Compact and mobile phototherapy units: Increasing usage in rural and home-care settings

Product innovation is accelerating adoption. For example, Cook Medical’s launch of the MINC+ Benchtop Incubator in March 2022 strengthened the country’s commitment to advanced neonatal and IVF care technologies. Such developments encourage hospitals to continually upgrade their devices, contributing to sustained market growth.

3. Government Healthcare Support and Strong Infrastructure

Australia’s universal healthcare system, combined with federal and state-level initiatives targeting maternal and child health, provides the foundation for widespread adoption of phototherapy equipment. Public hospital procurement programs, rural health investments, and neonatal workforce development all contribute to easy accessibility of phototherapy treatment for newborns.

Government-driven neonatal improvement strategies emphasize:

NICU equipment modernization

Training programs for neonatal nurses

Outreach programs for remote Indigenous communities

Increased awareness of early infant health

This institutional support ensures that both public and private hospitals maintain modern, high-quality phototherapy systems.

Market Challenges

1. High Equipment Costs and Hospital Budget Constraints

Despite clear clinical benefits, advanced phototherapy devices—especially LED-based units—carry higher upfront costs. Smaller clinics and regional healthcare centers often face procurement challenges, delaying equipment upgrades. Limited budgets may also result in reliance on outdated legacy devices, affecting treatment consistency.

The absence of centralized procurement regulations in some states leads to disparities in equipment availability across regions.

2. Limited Access in Remote and Indigenous Areas

Australia’s vast geography presents ongoing healthcare accessibility challenges. Remote communities, especially Indigenous populations, may lack on-site NICUs or phototherapy infrastructure. Newborns often need to be transported to larger hospitals, resulting in delays that increase health risks.

Expanding mobile neonatal units, portable devices, and trained rural healthcare staff remains essential to bridging this critical care gap.

Australia Infant Phototherapy Device Market by Segment

1. By Light Source

Fluorescent Lamps

Once the industry standard, now gradually being phased out

Require frequent bulb replacements

Higher heat output raises safety and comfort concerns

Retain relevance in low-budget or rural healthcare settings

LED Phototherapy Units

Fastest-growing segment

Longer lifespan, energy efficiency, and superior phototherapy intensity

Preferred choice for hospitals and neonatal clinics nationwide

Quartz Halogen Lamps & Gas Discharge Tubes

Used in a limited capacity

Less efficient compared to LED alternatives

Primarily present in older setups or as backup systems

2. By Configuration

Mobile Devices

Ideal for flexible NICU layouts

Crucial for rural health outreach and inter-department mobility

Increasingly used in home-care programs under medical supervision

Fixed Devices

Standard choice for high-volume hospitals and NICUs

Offer stable, high-intensity phototherapy

Preferred in major hospitals with round-the-clock neonatal units

3. By End User

Hospitals

Largest market segment

Public and private hospitals prioritize neonatal equipment upgrades

Access to government subsidies and procurement programs enhances adoption

Neonatal Clinics

Growing steadily

Largely urban-based, offering specialized care

Increasing focus on neonatal comfort and advanced treatment

Regional Analysis

Victoria

Victoria stands out with a dense urban population and advanced healthcare facilities—particularly in Melbourne. Strong investments in neonatal health and continuous technology adoption keep the state at the forefront of the phototherapy device market.

Queensland

Queensland’s large geographical expanse creates a dual demand: high-tech phototherapy equipment in cities like Brisbane and mobile or portable units for remote areas. Government-led rural health initiatives play a key role in generating demand.

Tasmania

Despite its smaller population, Tasmania offers strong healthcare access. Hospitals in Hobart and Launceston employ state-of-the-art phototherapy devices, while smaller clinics increasingly use mobile units to serve remote communities.

Western Australia

Western Australia’s vast territory poses challenges similar to Queensland. While Perth is well-equipped with modern NICUs, expanding phototherapy access to remote Aboriginal communities remains a priority. Mobile and compact phototherapy units are increasingly used to fill service gaps.

Key Companies – Competitive Landscape

Major companies active in the Australian infant phototherapy device market include:

Ningbo David Medical Device Co., Ltd

Koninklijke Philips N.V.

General Electric Company

Inspiration Healthcare Group Plc

Drägerwerk AG & Co. KGaA

Ibis Medical Equipment & Systems Pvt. Ltd

Weyer GmbH

Natus Medical Incorporated

Each company is analyzed through:

Overview

Key Personnel

Recent Developments

SWOT Analysis

Revenue Analysis

Collectively, these players are investing in innovation, energy-efficient technologies, and rural healthcare penetration to strengthen their market presence in Australia.

Final Thoughts

The Australia Infant Phototherapy Device Market is on a steady upward trajectory, powered by increased neonatal screening, rising awareness of jaundice treatment, and continuous improvements in medical technology. The transition to LED-based, portable, and cost-efficient devices symbolizes the future of neonatal care across the country.

As hospitals modernize their NICUs and government health programs expand outreach services, the demand for advanced phototherapy devices will continue to grow steadily through 2033. The market’s transformation reflects Australia’s broader commitment to enhancing infant health outcomes, improving access to specialized treatments, and ensuring that even the most remote communities benefit from lifesaving neonatal technologies.